Thermo Fisher Scientific Inc. (NYSE:TMO) Given Average Recommendation of “Moderate Buy” by Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMOGet Free Report) has been assigned an average rating of “Moderate Buy” from the twenty-one brokerages that are currently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and seventeen have given a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $607.43.

TMO has been the subject of a number of recent analyst reports. Raymond James reaffirmed an “outperform” rating and issued a $667.00 price objective (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Wednesday, April 23rd. Scotiabank decreased their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a research report on Friday, April 25th. Finally, Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research report on Thursday, April 24th.

Check Out Our Latest Analysis on Thermo Fisher Scientific

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at $59,506,950.58. This represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company’s stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 14,075 shares of company stock valued at $7,305,942. Insiders own 0.33% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp raised its stake in shares of Thermo Fisher Scientific by 19.6% in the 1st quarter. Jones Financial Companies Lllp now owns 103,983 shares of the medical research company’s stock valued at $51,920,000 after buying an additional 17,068 shares in the last quarter. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific in the first quarter worth about $30,000. Strs Ohio acquired a new position in Thermo Fisher Scientific in the first quarter worth about $98,500,000. Intrua Financial LLC raised its holdings in shares of Thermo Fisher Scientific by 11.6% in the 1st quarter. Intrua Financial LLC now owns 579 shares of the medical research company’s stock worth $288,000 after buying an additional 60 shares in the last quarter. Finally, Foresight Group Ltd Liability Partnership raised its holdings in shares of Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company’s stock worth $29,113,000 after buying an additional 56,747 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Performance

TMO opened at $402.41 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific has a fifty-two week low of $390.50 and a fifty-two week high of $627.88. The firm has a market cap of $151.91 billion, a PE ratio of 24.34, a P/E/G ratio of 2.99 and a beta of 0.82. The business has a fifty day simple moving average of $430.85 and a 200-day simple moving average of $499.77.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same period last year, the company posted $5.11 earnings per share. The business’s revenue for the quarter was up .2% on a year-over-year basis. As a group, equities analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

About Thermo Fisher Scientific

(Get Free Report

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Recommended Stories

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.